Fractyl Health, Inc. Common Stock

Fractyl Health, Inc. Common Stock Earnings Recaps

GUTS Healthcare 3 recaps
Next earnings: April 5, 2027 (estimated) · full calendar
Q3 2026 Nov 14, 2026

Fractyl Health rose 11.3% after reporting that REMAIN-1 met its six-month co-primary endpoint, supporting the potential of Revita to help patients maintain weight loss after stopping tirzepatide. The result is encouraging, but the 12-month endpoint remains unreported and is expected in Q1 2027.

Key takeaways
  • In REMAIN-1, participants lost an average of 18.3% of body weight on tirzepatide before stopping treatment; 308 participants were included in the modified intention-to-treat population.
  • At six months, Revita participants retained about 80% of their prior weight loss; the co-primary endpoint was met with a p-value of 0.0023.
  • Management reported that the separation from sham widened from months 1 to 6. A post hoc analysis found the best-performing patients, treated over roughly 20 centimeters or more, had less than half the weight regain of sham.
  • One in three Revita participants were weight-stable or had lost more weight six months after stopping tirzepatide, and nearly half retained at least 80% of their weight loss.
  • The company reported no device- or procedure-related serious adverse events, deaths, or unanticipated adverse device effects. The formal 12-month endpoint is expected in Q1 2027; management also said a de novo application is planned later this quarter.
Q1 2026 May 13, 2026

Shares fell 4.6% as investors reacted to cautious outlook signals, including slower-than-expected momentum in the pivotal trial enrollment and an extended timeline to top-line data, raising concerns about near-term value realization.

Key takeaways
  • The pivotal REMAIN-1 trial completed randomization in February with over 300 participants across 30+ U.S. sites, but the market appears concerned about the pace and timing of data readout.
  • Co-primary endpoints focus on mitigating weight regain at 6 months post-tirzepatide discontinuation and maintaining ≥5% weight loss at 52 weeks; top-line results are expected in early Q4 2026.
  • Participant retention remains high (>90%), and adverse events align with prior studies, supporting trial continuity but offering no immediate upside.
  • Management reaffirmed no planned capital raise before pivotal data, yet the extended timeline limits visibility on near-term catalysts.
  • FDA feedback continues to favor a moderate-risk device classification, with submission anticipated late Q4 2026 contingent on the 6-month data.
Q3 2025 Nov 14, 2025

Fractyl Health achieved a significant milestone in Q3 2025 by demonstrating the efficacy of its Revita procedure in maintaining weight loss after the discontinuation of GLP-1 therapy, while also strengthening its financial position for upcoming clinical milestones.

Key takeaways
  • Successfully reported randomized double-blind data indicating sustained weight loss in Revita-treated patients post-GLP-1 therapy, a critical advancement in obesity treatment.
  • Clinical programs are ahead of schedule, with over 60% of patient randomizations for the pivotal REMAIN one cohort completed.
  • Upcoming catalysts include six-month data from multiple cohorts and pivotal study results expected in 2026, positioning Revita for potential transformative impact in metabolic medicine.
  • Real-world studies further validate Revita's efficacy, showing significant weight loss and reductions in HbA1c in patients with type 2 diabetes over extended follow-up periods.